Mirum Pharmaceuticals, Inc. MIRM Fair Value Measurement Disclosure
Fair Value Measurement Disclosure at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FinancialLiabilitiesFairValueDisclosure.
The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mirum Pharmaceuticals, Inc.'s fair value measurement disclosure.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s fair value measurement disclosure?
- Mirum Pharmaceuticals, Inc. (MIRM) reported fair value measurement disclosure of $48.26M in Q1 2026.
- What does fair value measurement disclosure mean?
- This represents the aggregate carrying amount of assets and liabilities that are measured at fair value on a recurring or non-recurring basis. It provides transparency into the valuation techniques and inputs used to determine these values, categorized by the fair value hierarchy. This is critical for asset managers holding diverse investment portfolios.